Saline-filled intragastric balloons (IB) may be inserted for 6 months to promote weight loss. We aimed to assess potential benefits of repeating IB therapy.
One hundred eighteen consecutive subjects (median body mass index, 34.0 kg/m2; interquartile range [IQR], 31.2–36.9) treated with IB were included in a prospective non-randomized multicenter study.
Nineteen (16%) subjects had repeat IB therapy at their own request, either to prolong first treatment (n = 8) or after a IB-free interval (n = 11). Higher weight loss 3 months after first IB insertion independently predicted repeat therapy (P = 0.008). Median weight loss in subjects who had repeat therapy was lower with second vs first IB (9.0 vs 14.6 kg; 30.4% vs 49.3% excess weight [EW]; P = 0.003). Compared to subjects with single treatment (n = 99), those with repeat treatment (n = 19) had greater weight loss at first IB extraction (14.6 vs 11.0 kg; 49.3% vs 30.7% EW; P = 0.026) and 1 year later (12.0 vs 6.0 kg; 40.9% vs 20.8% EW; P = 0.008) but the difference became less than 2 kg starting at 3 years. At final follow-up (4.9 years; IQR, 3.4–6.7), the whole subject population had lost a median of 2.0 kg (IQR, −3.0 to 10.3) or 6.2% EW (IQR, −8.1 to 31.6) and identical proportions of subjects with single/repeat treatment had ≥10% baseline weight loss (26%) or bariatric surgery (32%).
Higher weight loss at 3 months independently predicted repeat IB therapy; weight loss with the second IB was lower compared to first IB. Repeat treatment had no effect on proportions of subjects with ≥10% baseline weight loss or bariatric surgery at final follow-up.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
body mass index
last observation carried forward
Dumonceau JM. Evidence-based review of the bioenterics intragastric balloon for weight loss. Obes Surg. 2008;18:1611–7.
Genco A, Cipriano M, Bacci V, et al. BioEnterics Intragastric Balloon (BIB): a short-term, double-blind, randomised, controlled, crossover study on weight reduction in morbidly obese patients. Int J Obes. 2006;30:129–33.
Martinez-Brocca MA, Belda O, Parejo J, et al. Intragastric balloon-induced satiety is not mediated by modification in fasting or postprandial plasma ghrelin levels in morbid obesity. Obes Surg. 2007;17:649–57.
Mathus-Vliegen EM, Tytgat GN. Intragastric balloon for treatment-resistant obesity: safety, tolerance, and efficacy of 1-year balloon treatment followed by a 1-year balloon-free follow-up. Gastrointest Endosc. 2005;61:19–27.
National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults—the evidence report. Obes Res. 1998;6 Suppl 2:51S–209.
Zago S, Kornmuller AM, Agagliati D, et al. Benefit from bio-enteric Intra-gastric balloon (BIB) to modify lifestyle and eating habits in severely obese patients eligible for bariatric surgery. Minerva Med. 2006;97:51–64.
Lorentz FH. Der konstitutionsindex der frau. Klin Wochenshr. 1929;16:734–6.
Doldi SB, Micheletto G, Perrini MN, et al. Treatment of morbid obesity with intragastric balloon in association with diet. Obes Surg. 2002;12:583–7.
Francica G, Giardiello C, Iodice G, et al. Ultrasound as the imaging method of choice for monitoring the intragastric balloon in obese patients: normal findings, pitfalls and diagnosis of complications. Obes Surg. 2004;14:833–7.
Douketis JD, Macie C, Thabane L, et al. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes. 2005;29:1153–67.
Dansinger ML, Tatsioni A, Wong JB, et al. Meta-analysis: the effect of dietary counseling for weight loss. Ann Intern Med. 2007;147:41–50.
Eddy DM, Schlessinger L, Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med. 2005;143:251–64.
Machytka E, Klvana P, Hanuskova L, et al. Use of pharmacotherapy for long-term maintenance of weight loss following explantation of intragastric balloon (BIB). Gut. 2007;57:A290.
Padwal R, Kezouh A, Levine M, et al. Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes. 2007;31:1567–70.
Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007;337:1194–9.
Williamson DF. Pharmacotherapy for obesity. JAMA. 1999;281:278–80.
Melissas J, Mouzas J, Filis D, et al. The intragastric balloon—smoothing the path to bariatric surgery. Obes Surg. 2006;16:897–902.
Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70.
Roman S, Napoleon B, Mion F, et al. Intragastric balloon for “non-morbid” obesity: a retrospective evaluation of tolerance and efficacy. Obes Surg. 2004;14:539–44.
Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon. Obes Surg. 2004;14:991–8.
Evans JD, Scott MH. Intragastric balloon in the treatment of patients with morbid obesity. Br J Surg. 2001;88:1245–8.
Potential Conflicts of Interests
The authors declare that they have no conflict of interest.
No funding was obtained for this work.
About this article
Cite this article
Dumonceau, JM., François, E., Hittelet, A. et al. Single vs Repeated Treatment with the Intragastric Balloon: A 5-Year Weight Loss Study. OBES SURG 20, 692–697 (2010). https://doi.org/10.1007/s11695-010-0127-x
- Gastrointestinal endoscopy
- Gastric balloon
- Weight loss